March 29, 2005 -- After starting off the day positively, stocks moved lower through the mid and late stages of the trading session, closing near their lows. The Centient Biotech 200 ost .69%, dropping 22 points to close at 3142.84. The NYSE Composite was off .86%, and the Nasdaq was .94% lower. Pfizer won FDA approval of a second indication for its injected contraceptive, Baxter got the right to distribute WinRho SDF, a clotting drug, Theravance received Fast-Track designation for Telavancin, an antibiotic for pneumonia, Andrx specified terms for its sale/licensing agreements, Immunomedics announced two late-stage lupus trials, and Ivax and Mylan both received FDA approval for generic versions of popular medicines. More details...
